Darbepoetin alfa
Darbepoetin alfa (Aranesp) is a longer-acting version of erythropoietin given every one to three weeks to treat anaemia caused by chemotherapy, reducing transfusions but with the same warnings about clots and tumour growth as epoetin.
Overview
Darbepoetin alfa was approved by the FDA in September 2001 for anaemia of chronic kidney disease and in July 2002 for anaemia due to concomitant myelosuppressive chemotherapy in non-myeloid malignancies with at least two further months of planned chemotherapy; the EU authorised Aranesp in June 2001. Weekly or three-weekly dosing suited chemotherapy schedules and it displaced much epoetin use in oncology before the survival and thrombosis findings of the 2000s (including the darbepoetin trial in anaemic cancer patients not on chemotherapy, which showed excess mortality) restricted all erythropoiesis-stimulating agents to the lowest dose needed to avoid transfusion in the palliative setting. The label states it has not been shown to improve quality of life or fatigue. Hypertension, thromboembolism and rare pure red cell aplasia are the main risks.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2001 | Anaemia of chronic kidney disease |
| US | 2002 | Anaemia due to concomitant myelosuppressive chemotherapy in non-myeloid malignancies |
| EU | 2001 | Anaemia of chronic renal failure; symptomatic anaemia in adults with non-myeloid malignancies receiving chemotherapy (Aranesp) |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Darbepoetin alfa" OR ABSTRACT:"Darbepoetin alfa" OR TITLE:"Aranesp" OR ABSTRACT:"Aranesp") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Darbepoetin alfa, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductPegfilgrastim
Shares Amgen and the tags nci-list, supportive.
- ProductFilgrastim (G-CSF)
Shares Amgen and the tags nci-list, supportive.
- ProductDenosumab
Shares Amgen and the tags nci-list, supportive.
- ProductAmifostine
Shares the tags nci-list, supportive.
- ProductAprepitant (and fosaprepitant)
Shares the tags nci-list, supportive.
- ProductDefibrotide
Shares the tags nci-list, supportive.
- ProductDexrazoxane
Shares the tags nci-list, supportive.
- ProductGlucarpidase
Shares the tags nci-list, supportive.